MeSH tree: C04.557.386.480.150
Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at the annual hybrid congress ...
Jun 26, 2024
0
0
Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer ...
Jun 19, 2024
0
35
Researchers from the University of Helsinki and HUS investigated the effects of recurring mutations in the KLHL6 gene in diffuse large B-cell lymphoma, the most common cancer of the lymphatic system.
Jun 18, 2024
0
0
Graduate student Hillary Layden studies transcriptional control of cancer in the lab of Scott Hiebert, Hortense B. Ingram Chair in Cancer Research and professor of biochemistry.
May 30, 2024
0
0
A team of cancer researchers, led by the University of Houston, has discovered a new subset of T cells that may improve the outcome for patients treated with T-cell therapies.
May 28, 2024
0
40
Researchers from the Cancer Science Institute of Singapore (CSI) at the National University of Singapore (NUS), have achieved breakthroughs in understanding relapse after chemotherapy for a type of cancer known as diffuse ...
May 13, 2024
0
15
Patients being treated for B-cell non-Hodgkin's Lymphoma (NHL) who are part of minority populations may not have equal access to cutting-edge CAR T cell therapies, according to a new analysis led by researchers from the Perelman ...
Mar 26, 2024
0
0
Patients with some types of lymphoma that become resistant to standard treatments may benefit from a therapy that University of Wisconsin–Madison researchers are evaluating after they discovered a key process that fuels ...
Mar 16, 2024
0
48
In treating aggressive lymphomas and blood cancer (leukemia), chimeric antigen receptor T cells (CAR T cells) are increasingly being used. For this therapy, immune cells are taken from patients and programmed by means of ...
Feb 9, 2024
0
59
As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies. In work published ...
Feb 5, 2024
0
0
